Latest studies
- Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusChile - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaChile - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseChile - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaChile - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Chile - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsChile - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinChile - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVChile - Active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
MelanomaChile - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisChile - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerChile - Active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
MelanomaChile - Recruiting
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
This study looks at how a new scoring system helps doctors decide the best treatment for broken bones in the back caused by osteoporosis. It compares how well patients do when doctors follow the score's advice versus when they choose a different path.
Osteoporotic FracturesOsteoporosisChile - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesChile - Active not recruitingPHASE3
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is looking into a new drug, garetosmab, for adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to find out if it's safe, how well it works, and if it helps with FOP symptoms. It's a Phase 3 trial, meaning it's in the later stages of testing.
Fibrodysplasia Ossificans ProgressivaChile - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaChile - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsChile - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerChile - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerChile - RecruitingPHASE3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
This study looks at a new drug, zolbetuximab, alongside usual treatments for stomach or gullet cancer that has spread or can't be removed. It aims to see if this combination helps people live longer by targeting specific proteins on cancer cells.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChile - RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This study is looking at a new treatment called petosemtamab for advanced head and neck cancer. It compares this new drug with standard treatments chosen by doctors, for patients whose cancer has come back or spread after previous therapies.
Head and Neck Squamous Cell CarcinomaChile - Active not recruitingPHASE3
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
This study looks at the safety of a two-in-one medicine called DOR/ISL for adults with HIV-1. It's for people who have already taken this medicine in other research studies. The main goal is to see how well people tolerate it over time.
HIV InfectionChile - RecruitingNA
ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds
This study looks at a new type of wound therapy called ConvaVAC™ Ag+ to see if it helps heal long-lasting leg ulcers. It aims to find out how safe and effective this special dressing system is for these wounds.
Venous Leg Ulcer (VLU)Chile - Not yet recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisChile - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerChile - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisChile - RecruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
Metastatic Castration-Resistant Prostate CancerChile - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureChile - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisChile - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesChile - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCChile - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisChile - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
Non-small Cell Lung CancerChile - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisChile - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
Heart FailureChile - RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
HER2-positive Breast CancerChile - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisChile - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
ArteriosclerosisHypercholesterolaemiaChile - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
Biliary Tract CancerChile - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerChile - Active not recruitingPHASE3
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
This study is for people with COPD who have been in previous trials (OBERON or TITANIA). It looks at the long-term effects of a medicine called Tozorakimab, comparing it to a dummy treatment, to see if it's safe and helps reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)Chile - Active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
MelanomaChile - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
This study looks at a new medicine called amlitelimab for people aged 12 and over with moderate-to-severe eczema. These individuals haven't responded well to other common eczema treatments. Researchers want to see if amlitelimab is safe and helps improve their skin when used with their usual steroid creams.
Dermatitis AtopicChile - Active not recruitingPHASE1, PHASE2
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This study is testing a new drug called RO7126209 for people with early Alzheimer's disease. We want to see how safe it is, how well the body handles it, and if it affects the disease. Participants will receive the drug intravenously.
Alzheimers DiseaseChile - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
Breast NeoplasmsChile - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerChile - RecruitingPHASE3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
This study is for people who have already taken part in certain Incyte povorcitinib trials for Hidradenitis Suppurativa (HS) and found the treatment helpful. It allows them to continue receiving the study drug if their doctor agrees it's safe and beneficial.
Hidradenitis Suppurativa (HS)Chile - RecruitingPHASE2
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
This study is testing a new medicine, tibulizumab, for an illness called systemic sclerosis (scleroderma). We want to see if it helps improve symptoms over 24 weeks, followed by an additional 28 weeks where everyone gets the study drug.
Systemic Sclerosis (SSc)SclerodermaChile - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Afimkibart for people with moderate to severe ulcerative colitis. It aims to see how well it works and if it's safe compared to a dummy drug. The study is for adults aged 16 to 80 who haven't found existing treatments helpful.
Moderately to Severely Active Ulcerative ColitisChile - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerChile